Titel: Life Science Conference + Expo 2006: Indispensable Technologies Driving Discovery, Development, and Clinical Trials
Termin:
3.4.2006
Veranstaltungsort:
39 Dalton Street
Boston, MA 02199
USA
Referenten: Samuel Aaronson (Partners) *** Edwin Addison (Teradisc) *** Dimitris Agrafiotis (Johnson & Johnson) *** Christopher Ahlberg (Spotfire) *** Ken Baclawski (Northeastern University) *** Landen Bain (Topsail Technologies) *** Alex Bangs (Entelos) *** Paul Bleicher (Phase Forward) *** Jason Burke (SAS) *** Stephen Calvert (GlaxoSmithKline) *** Howard Cash (Gene Codes) *** Bill Cheliak (Genizon) *** George Church (Harvard) *** John Cline (eTrials) *** Derek Debe (Eidogen-Sertanty) *** David de Graaf (Pfizer) *** Ramon Dempers (ICM Corp.) *** Don Detmer (AMIA) *** Tomithy Dion (Biogen-Idec) *** Patricia Dombrowski (Bellevue Community College) *** Chris Dwan (BioTeam) *** Seth Earley (Earley & Associates) *** Keith Elliston (Genstruct) *** Mich Fisher (Revivio) *** Ian Fore (NCI) *** Eric Gerritsen (BioPeer) *** Kenneth Getz (Tufts CSDD) *** Jim Golden (SAIC) *** David Goldstein (Duke University) *** Karen F. Green (Wilmer Cutler Pickering Hale and Dorr) *** Imogene Grimes (Regeneron Pharmaceuticals) *** Sam Grocott (Isilon) *** John Halamka (Harvard Medical School) *** Timo Hanney (Nature Publishing Group) *** Susan Hardin (Visigen) *** David Hardison (SAIC) *** Ed Helton (SAS) *** Bill Hersh (Oregon Health Sciences Univ.) *** Alan Hochberg (ProSanos) *** Andrew Hopkins (Pfizer, UK) *** Charles Jaffe (Intel) *** John Keilty (Infinity) *** Liz Kerr (Apple) *** Walter Koch (Roche) *** Bryan Koontz (Tripos) *** Ray Kurzweil *** Rebecca Kush (CDISC) *** Paul Lammers (Serono) *** Sean Lanagan (EMC) *** Martin Leach (Booz Allen Hamilton) *** Ben Li (Neurogen) *** Kris Lichter (IBM) *** Steve Lincoln (Affymetrix) *** Scott Lundstrom (Health Industry Insights) *** Gary Lupin (Merck) *** Ilya Mazo (Ariadne Genomics) *** Charles Mead (Oracle) *** Michael McManus (Fujitsu) *** Jill Mesirov (Broad Institute) *** David Milward (Linguamatics) *** Jules Mitchel (Target Health) *** William Moffit (Nanosphere) *** George Morris (NIBR) *** Eric Neumann (Teranode) *** Tatiana Nikolskaya (GeneGo) *** Tim OReilly (OReilly) *** Jean Paty (invivodata) *** Bryan Pearce (Ernst & Young) *** Michael Peeler (SciTegic) *** Manuel Peitsch (Novartis) *** James Reaney (Blue Arc) *** John Reynders (Eli Lilly) *** Glenn Rice (Bridge Pharmaceuticals) *** Allen Roses (GlaxoSmithKline) *** Jonathan Rothberg (454) *** Don Rule (Microsoft) *** Sal Salamone (Bio-IT World) *** Eric Selfen (Columbia University) *** Matt Shanahan (Teranode) *** Jonathan Shapiro (Wilmer Cutler Pickering Hale and Dorr) *** David Shiple *** Kari Stefansson (DeCODE Genetics) *** Dietrich Stephan (TGen) *** Susie Stephens (Oracle) *** Don Taylor (Vivisimo) *** Uwe Trinks (Sentrx) *** Lex Van Der Ploeg (Merck) *** Robbert Van Manen (Lincoln Technologies) *** Marc Vidal (Harvard Medical School) *** Cynthia Vreeland (Wilmer Cutler Pickering Hale and Dorr) *** John West (Solexa) *** Jim Wikel (Coalesix) *** Deborah Zarin (NIH)
Weitere Informationen:
http://www.lifesciencesexpo.com/
Life Sciences Conference + Expo 2006 features four primary conference tracks, complemented by several instructional workshops, where bioscience executives, IT professionals and scientists will learn how to utilize technology and informatics to more effectively create, store and analyze data. The result: accelerating the R&D process and speeding time to market.
Track 1 GENOMIC MEDICINE AND TECHNOLOGY
It is almost five years since the first announcement of the draft sequence of the human genome. Remarkable progress has been made since that time: the genomes of more than 300 organisms
have been sequenced, microarray profiling is producing molecular fingerprints of cancer and other diseases; dramatic reductions in the cost of genotyping and sequencing technology have produced the international HapMap and ushered realistic scenarios of the $1,000 Genome; and the interplay of highthroughput molecular and simulation approaches is leading to the rapid maturation of systems biology.
"Genomic Medicine and Technology" features seven sessions that will explore these themes with an outstanding faculty from academia, biotech and pharma.
Track 2 IT/INFORMATICS SOLUTIONS FOR
DRUG DISCOVERY
Managing, analyzing and sharing data across silos, departments, and organizations remains the prime challenge for most life sciences organizations. From building a state-of-the-art IT infrastructure at a new pharma facility to optimizing the
information workflow within an existing company, to deploying algorithms for rational drug design to devising new Semantic Web standards and methodologies to share and retrieve information, the importance of informatics and IT in drug
discovery and development has never been greater.
This track features a magnificent line-up of speakers from industry and academia who will share knowledge, insight and recommendations to enhance the drug discovery pipeline.
Track 3 E-CLINICAL RESEARCH AND TRIALS
The clinical research enterprise faces numerous challenges including rising costs, intense competition, regulatory pressures and shortages of qualified professionals and patients. Scientists,
project managers and clinical staff are placing a premium on new e-Research technologies to streamline performance,
increase efficiency, coordinate patient recruitment and recordkeeping, and improve regulatory compliance.
This track explores critical issues around planning, implementing and managing a variety of e-Clinical research solutions, including the adoption of comprehensive EDC systems,
IVRS and e-Diaries; integration with electronic medical record systems; adoption and use of data interchange standards; emerging patient recruitment and retention solutions; drug safety and pharmacovigilance strategies; and organizational approaches to implementing e-Clinical technologies.
Track 4 THE IDG VENTURE SUMMIT
The 2006 IDG Venture Summit, co-organized by Ernst & Young, is a compelling one-day event that unites the biopharma and investment communities. The track will provide expert, in-depth
analysis on the investment landscape for both the biotech and biopharma technology industries. It will provide attendees with a clearer understanding of where the R&D markets are heading,
where monies are being invested, and spotlight several organizations that are positioning themselves to be the future
drivers of these technological advances.
Kontakt:
Life Sciences Conference + Expo
PO Box 380080
Boston, MA 02241
USA
Tel.:
+1 - 805 - 6 77 42 95
Fax: +1 - 805 - 6 54 16 76
lifesciencesexpo2006@rcsreg.com
http://www.lifesciencesexpo.com/
Veranstalter: Massachusetts Biotechnology Council, Bio-IT World
Schlagworte: Biotechnologie, Genetische Tests/Beratung, Genforschung/-technik, Genomanalyse, Gentherapie, Humangenetik, Pharmazeutik, Technikethik, Wissenschaftsethik